For the year ending 2025-12-31, BBIO had -$111,104K decrease in cash & cash equivalents over the period. -$447,007K in free cash flow.
| Cash Flow | 2025-12-31 |
|---|---|
| Net loss | -732,938 |
| Stock-based compensation | 133,024 |
| Loss on extinguishments of debt | -21,155 |
| Noncash interest expense on deferred royalty obligations | 125,138 |
| Amortization of debt discount and issuance costs | 5,967 |
| Depreciation and amortization | 5,434 |
| Noncash lease expense | 4,902 |
| Net loss from equity method investments | -72,608 |
| Change in fair value of the embedded derivative associated with the deferred royalty obligation | 19,652 |
| Noncash income from equity method investments | 8,833 |
| (gain) loss on deconsolidation of subsidiaries | 0 |
| Gain from investment in equity securities, net | 0 |
| Accrual of payment-in-kind interest on term loan | 0 |
| Other noncash adjustments, net | 1,651 |
| Accounts receivable, net | 134,722 |
| Inventories | 25,307 |
| Prepaid expenses and other current assets | 8,777 |
| Other assets | -1,113 |
| Accounts payable | 26,609 |
| Accrued compensation and benefits | 23,022 |
| Accrued research and development liabilities | 7,163 |
| Operating lease liabilities | -6,547 |
| Deferred revenue | -11,428 |
| Other liabilities | 77,810 |
| Net cash used in operating activities | -445,910 |
| Purchases of marketable securities | 28,197 |
| Maturities of marketable securities | 11,000 |
| Purchases of investments in equity securities | 0 |
| Proceeds from sales of investments in equity securities | 0 |
| Proceeds from special cash dividends received from an investment in equity securities | 2,302 |
| Payment for intangible assets | 8,495 |
| Purchases of property and equipment | 1,097 |
| Decrease in cash and cash equivalents resulting from deconsolidation of subsidiaries | 0 |
| Net cash provided by (used in) investing activities | -24,487 |
| Proceeds from issuance of 2031 notes-A2031Convertible Senior Notes | 575,000 |
| Issuance costs and discounts associated with 2031 notes/ issuance costs and discounts associated with term loan under amended financing agreement-A2031Convertible Senior Notes | 12,034 |
| Repurchase of common stock | 48,276 |
| Proceeds from royalty obligation-Royalty Interest Purchase And Sale Agreement | 300,000 |
| Issuance costs and discounts associated with a royalty obligation-Royalty Interest Purchase And Sale Agreement | 3,010 |
| Proceeds from royalty obligation-Funding Agreement | 0 |
| Issuance costs and discounts associated with a royalty obligation-Funding Agreement | 0 |
| Proceeds from term loan under the amended financing agreement-Financing Agreement | 0 |
| Issuance costs and discounts associated with 2031 notes/ issuance costs and discounts associated with term loan under amended financing agreement-Financing Agreement | 0 |
| Repayment of term loans | 459,000 |
| Repayments of deferred royalty obligations | 15,460 |
| Proceeds from issuance of common stock through public offerings, net | 0 |
| Proceeds from common stock issuances under espp | 6,414 |
| Proceeds from stock option exercises, net of repurchases | 27,735 |
| Transactions with noncontrolling interests | 2,150 |
| Repurchase of rsu shares to satisfy tax withholding | 14,226 |
| Net cash provided by financing activities | 359,293 |
| Net increase (decrease) in cash, cash equivalents, and restricted cash | -111,104 |
| Cash, cash equivalents, and restricted cash at beginning of year | 683,244 |
| Cash, cash equivalents, and restricted cash at end of year | 572,140 |
BridgeBio Pharma, Inc. (BBIO)
BridgeBio Pharma, Inc. (BBIO)